PATENT CLAIM ANALYSIS

Application Number: 15952516
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "006800"]

Abstract:
Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a β-Klotho-binding protein, an FGFR1-binding protein, a β-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.

Claim (Index 26):
The method of  claim 1 , wherein the at least one point mutation in the mutant FGF1 protein comprises one or more of the mutations shown in Table 1, wherein the mutated FGF1 protein has reduced mitogenic activity as compared to wild-type mature FGF1 protein.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 91.0
- Lexical Diversity: 1.5614
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14520178', '14176992', '15283862', '15896469', '13641041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8099175065495272
- 35 USC 102 Novelty (BERT): 0.6179267720182404
- Combined Prediction Score: 0.7907184330963986
- Mean Citation Score: 436.727788
- Max Citation Score: 675.9603
- Similarity Product: 475.9301988834858

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test